Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Overall Survival
100%
Malignant Neoplasm
60%
Hepatocellular Carcinoma
54%
Chemoradiotherapy
50%
Diseases
48%
Chemotherapy
39%
Progression Free Survival
36%
Acute Myeloid Leukemia
35%
Neoplasm
25%
positron emission tomographic scan
23%
Clinical Trial
22%
Nivolumab
21%
Transitional Cell Carcinoma
21%
Biological Marker
21%
Arm
20%
Esophageal Cancer
20%
Hazard Ratio
19%
Venetoclax
19%
Pancreas Cancer
18%
Standardized Uptake Value
18%
Adverse Event
16%
Clear Cell Renal Cell Carcinoma
16%
Radiation Therapy
15%
Somatomedin C
13%
Acute Lymphoblastic Leukemia
13%
Survival Rate
13%
Immune Checkpoint Inhibitor
13%
Cytarabine
12%
Tyrosine-Kinase Inhibitor
12%
Fludarabine
12%
Breast Cancer
11%
Carcinoma
11%
Proportional Hazards Model
11%
Histology
11%
Recurrent Disease
11%
Cholangiocarcinoma
11%
Neoadjuvant Chemotherapy
11%
Recurrence Free Survival
11%
Stomach Adenocarcinoma
10%
Biliary Tract Cancer
10%
Odds Ratio
10%
Kidney Metastasis
10%
Tumor
10%
Multivariate Analysis
10%
Adenocarcinoma
10%
Cisplatin
9%
Idarubicin
9%
Phase II Trials
9%
Distant Metastasis
9%
Scoring System
8%
Keyphrases
Overall Survival
73%
Hepatocellular Carcinoma
50%
95% Confidence Interval
42%
Acute Myeloid Leukemia
33%
Nivolumab
31%
Progression-free Survival
27%
Median Overall Survival
26%
Patient Outcomes
25%
Chemoradiation
24%
Positron Emission Tomography/computed Tomography (PET/CT)
23%
Newly Diagnosed
23%
Phase II Trial
22%
Esophageal Cancer
20%
Phase I Study
20%
Advanced Hepatocellular Carcinoma
19%
Metastatic Renal Cell Carcinoma (mRCC)
19%
Venetoclax
19%
Standardized Uptake Value
17%
Hazard Ratio
17%
Upper Tract Urothelial Carcinoma
17%
Chemotherapy
15%
Hepatocellular Carcinoma Patient
15%
Pathological Complete Response
15%
High Risk
14%
Ipilimumab
14%
Growth Factors
13%
Insulin-like
13%
Immune Checkpoint Inhibitors
13%
Median Progression-free Survival
13%
Prognostic Biomarker
13%
Phase I Trial
13%
Cytarabine
13%
Cancer Patients
13%
MD Anderson Cancer Center
13%
Complete Remission
12%
Idarubicin
12%
Gastroesophageal Carcinoma
12%
Relapsed/refractory Acute Myeloid Leukemia
12%
Nomogram
12%
Pancreatic Cancer
12%
Patient Survival
12%
Clinical Outcomes
11%
Adverse Events
11%
Definitive Chemoradiation
11%
Multivariate Analysis
11%
Previously Treated
11%
Tumor
11%
FLAG-Ida
10%
Center Experience
10%
Partial Response
10%